BioCardia (BCDA) CFO granted 60,483 RSUs as stock compensation
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BioCardia, Inc. reported that Chief Financial Officer David McClung acquired 60,483 shares of common stock through a grant of restricted stock units (RSUs) awarded as compensation in lieu of cash. Each RSU represents one share of common stock, and 100% of the RSUs vested on June 29, 2026. Following this award, McClung directly owns 137,370 shares of BioCardia common stock. This is a compensation-related equity grant rather than an open-market share purchase.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
McClung David
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 60,483 | $1.20 | $73K |
Holdings After Transaction:
Common Stock — 137,370 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
RSU grant size: 60,483 shares
RSU grant price: $1.20 per share
Shares owned after grant: 137,370 shares
3 metrics
RSU grant size
60,483 shares
Restricted stock units awarded to CFO on June 29, 2026
RSU grant price
$1.20 per share
Reported value per share for 60,483 RSUs
Shares owned after grant
137,370 shares
CFO’s direct BioCardia common stock holdings following the RSU vesting
Key Terms
restricted stock units ("RSUs"), compensation in lieu of cash, Common Stock
3 terms
restricted stock units ("RSUs") financial
"The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right..."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
compensation in lieu of cash financial
"common stock awarded as compensation in lieu of cash. 100% of the RSUs vested on June 29, 2026."
Common Stock financial
"security_title": "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
What insider transaction did BioCardia (BCDA) report for its CFO?
BioCardia reported that CFO David McClung received a grant of 60,483 restricted stock units, each representing one share of common stock. The award was given as compensation in lieu of cash and fully vested on June 29, 2026, increasing his direct holdings.
Was the BioCardia (BCDA) CFO’s transaction a market purchase or a stock grant?
The transaction was a stock grant, not a market purchase. David McClung acquired 60,483 shares via restricted stock units awarded as compensation in lieu of cash, with all units vesting on June 29, 2026, rather than buying shares in the open market.
At what price were the BioCardia (BCDA) RSUs for the CFO valued?
The restricted stock units granted to CFO David McClung were reported at a value of $1.20 per share for 60,483 shares. This valuation applies to the RSU award that vested in full on June 29, 2026, increasing his equity stake in BioCardia.
What does the RSU vesting schedule look like for the BioCardia (BCDA) CFO grant?
The RSU award to CFO David McClung vested 100% on June 29, 2026. This means all 60,483 restricted stock units converted into an equal number of BioCardia common shares on that date, with no remaining unvested portion from this particular grant.